journal article·2024-05Open access

Spatiotemporal Insights into Glioma Oncostream Dynamics: Unraveling Formation, Stability, and Disassembly Pathways

Syed M. Faisal, Jarred E. Clewner, Brooklyn Stack, Maria L. Varela, Andrea Comba, Grace Abbud, Sebastien Motsch, Maria G. Castro, Pedro R. Lowenstein

Advanced Science· Volume 11· Issue 18

Abstract

Abstract Glioblastoma (GBM) remains a challenge in Neuro‐oncology, with a poor prognosis showing only a 5% survival rate beyond two years. This is primarily due to its aggressiveness and intra‐tumoral heterogeneity, which limits complete surgical resection and reduces the efficacy of existing treatments. The existence of oncostreams—neuropathological structures comprising aligned spindle‐like cells from both tumor and non‐tumor origins‐ is discovered earlier. Oncostreams are closely linked to glioma aggressiveness and facilitate the spread into adjacent healthy brain tissue. A unique molecular signature intrinsic to oncostreams, with overexpression of key genes (i.e., COL1A1, ACTA2) that drive the tumor's mesenchymal transition and malignancy is also identified. Pre‐clinical studies on genetically engineered mouse models demonstrated that COL1A1 inhibition disrupts oncostreams, modifies TME, reduces mesenchymal gene expression, and extends survival. An in vitro model using GFP+ NPA cells to investigate how various treatments affect oncostream dynamics is developed. Analysis showed that factors such as cell density, morphology, neurotransmitter agonists, calcium chelators, and cytoskeleton‐targeting drugs influence oncostream formation. This data illuminate the patterns of glioma migration and suggest anti‐invasion strategies that can improve GBM patient outcomes when combined with traditional therapies. This work highlights the potential of targeting oncostreams to control glioma invasion and enhance treatment efficacy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Glioma Diagnosis and Treatment · Microtubule and mitosis dynamics · Caveolin-1 and cellular processes

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Neurosurgery University of Michigan Medical School Ann Arbor Michigan 48108 USA

Department of Cell and Developmental Biology University of Michigan Medical School Ann Arbor Michigan 48108 USA

Rogel Cancer Centre University of Michigan Medical School Ann Arbor Michigan 48108 USA

Department of Statistics and Mathematical Sciences Arizona State University Tempe Arizona 85287 USA

Department of Biomedical Engineering University of Michigan Medical School Ann Arbor Michigan 48108 USA

Funding

Ian's Friends Foundation · Pediatric Brain Tumor Foundation · NIH Blueprint for Neuroscience Research

References (58)

Show source-provided references
1. 10.1007/s00401-016-1545-110.1007/s00401-016-1545-1 ↗
2. 10.1093/neuonc/noab10610.1093/neuonc/noab106 ↗
3. 10.1002/path.303110.1002/path.3031 ↗
4. 10.1016/j.cell.2015.12.02810.1016/j.cell.2015.12.028 ↗
5. 10.1126/scitranslmed.300301610.1126/scitranslmed.3003016 ↗
6. 10.1073/pnas.121974711010.1073/pnas.1219747110 ↗
7. 10.1002/glia.2330910.1002/glia.23309 ↗
8. 10.3390/brainsci1204050510.3390/brainsci12040505 ↗
9. 10.1038/s41571-020-00447-z10.1038/s41571-020-00447-z ↗
10. 10.3174/ajnr.A746210.3174/ajnr.A7462 ↗
11. 10.1038/s41582-022-00679-w10.1038/s41582-022-00679-w ↗
12. 10.1080/13543784.2020.176852810.1080/13543784.2020.1768528 ↗
13. 10.1038/s41571-019-0177-510.1038/s41571-019-0177-5 ↗
14. 10.1056/NEJMoa04333010.1056/NEJMoa043330 ↗
15. 10.1080/14712598.2022.215771810.1080/14712598.2022.2157718 ↗
16. 10.3389/fonc.2021.63103710.3389/fonc.2021.631037 ↗
17. 10.1158/1078-0432.CCR-21-275010.1158/1078-0432.CCR-21-2750 ↗
18. 10.1001/jama.2017.1871810.1001/jama.2017.18718 ↗
19. 10.1001/jama.2018.185810.1001/jama.2018.1858 ↗
20. 10.1038/s41467-022-31262-y10.1038/s41467-022-31262-y ↗
21. 10.1038/s41591-022-01897-x10.1038/s41591-022-01897-x ↗
22. 10.1016/S1470-2045(23)00347-910.1016/S1470-2045(23)00347-9 ↗
23. 10.3389/fnmol.2021.62183110.3389/fnmol.2021.621831 ↗
24. 10.1016/j.ymthe.2023.08.00910.1016/j.ymthe.2023.08.009 ↗
25. 10.18632/oncotarget.2783410.18632/oncotarget.27834 ↗
26. 10.1038/s41467-022-31340-110.1038/s41467-022-31340-1 ↗
27. 10.1126/sciadv.adf717010.1126/sciadv.adf7170 ↗
28. 10.1016/j.xpro.2023.10217410.1016/j.xpro.2023.102174 ↗
29. 10.3389/fonc.2021.70376410.3389/fonc.2021.703764 ↗
30. 10.1371/journal.pcbi.100761110.1371/journal.pcbi.1007611 ↗
31. 10.1038/ncb290610.1038/ncb2906 ↗
32. 10.1038/s41586-022-05520-410.1038/s41586-022-05520-4 ↗
33. 10.1016/j.tibs.2010.07.01310.1016/j.tibs.2010.07.013 ↗
34. 10.1038/d41586-022-04354-410.1038/d41586-022-04354-4 ↗
35. 10.1038/s41586-019-1564-x10.1038/s41586-019-1564-x ↗
36. Haeger A. · J. Exp. Med. · 2020 · 217
37. 10.1172/jci.insight.13526310.1172/jci.insight.135263 ↗
38. 10.1523/JNEUROSCI.2962-16.201610.1523/JNEUROSCI.2962-16.2016 ↗
39. 10.3389/fimmu.2023.109028810.3389/fimmu.2023.1090288 ↗
40. 10.1093/neuonc/noac209.106210.1093/neuonc/noac209.1062 ↗
41. 10.1093/neuonc/noad179.106910.1093/neuonc/noad179.1069 ↗
42. 10.1158/1538-7445.AM2023-583510.1158/1538-7445.AM2023-5835 ↗
43. 10.1242/jcs.22027710.1242/jcs.220277 ↗
44. 10.3389/fonc.2022.100506910.3389/fonc.2022.1005069 ↗
45. 10.15586/codon.glioblastoma.2017.ch510.15586/codon.glioblastoma.2017.ch5 ↗
46. 10.1242/dev.17205610.1242/dev.172056 ↗
47. 10.1038/embor.2012.14910.1038/embor.2012.149 ↗
48. 10.1097/CCO.000000000000067910.1097/CCO.0000000000000679 ↗
49. 10.1186/1741-7015-4-3810.1186/1741-7015-4-38 ↗
50. 10.1038/nrn376510.1038/nrn3765 ↗
51. 10.1126/scitranslmed.aac822810.1126/scitranslmed.aac8228 ↗
52. Nunez F. J. · Sci. Transl. Med. · 2019 · 11
53. Calinescu A. A. · J. Vis. Exp. · 2015 · 22
54. 10.1080/2162402X.2021.193960110.1080/2162402X.2021.1939601 ↗
55. 10.1021/acsnano.1c0749210.1021/acsnano.1c07492 ↗
56. Haase S. · J. Clin. Invest. · 2022 · 3
57. 10.1126/sciadv.abh324310.1126/sciadv.abh3243 ↗
58. 10.1073/pnas.201463911710.1073/pnas.2014639117 ↗